Clinical Trial Update: Apatinib Plus Etoposide Versus Etoposide Alone for Platinum-resistant Recurrent Ovarian Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating apatinib plus etoposide versus etoposide alone for platinum-resistant recurrent ovarian cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Apatinib (apatinib)
• Etoposide (Etoposide)

Snippet

Sponsor: Yang Zhijun | Conditions: Ovarian Cancer | Phase 2 | Status: UNKNOWN